Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies

NCT00458731 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00458731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00458731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
Not reported
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult grade iii lymphomatoid granulomatosis, adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, childhood burkitt lymphoma, childhood diffuse large cell lymphoma, childhood grade iii lymphomatoid granulomatosis, childhood immunoblastic large cell lymphoma, childhood nasal type extranodal nk/t-cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, intraocular lymphoma, nodal marginal zone b-cell lymphoma, noncutaneous extranodal lymphoma, peripheral t-cell lymphoma, progressive hairy cell leukemia, initial treatment, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent childhood anaplastic large cell lymphoma, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent/refractory childhood hodgkin lymphoma, refractory hairy cell leukemia, small intestine lymphoma, splenic marginal zone lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv childhood anaplastic large cell lymphoma, stage iv childhood hodgkin lymphoma, stage iv childhood large cell lymphoma, stage iv childhood lymphoblastic lymphoma, stage iv childhood small noncleaved cell lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iva mycosis fungoides/sezary syndrome, stage ivb mycosis fungoides/sezary syndrome, t-cell large granular lymphocyte leukemia, testicular lymphoma, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific, waldenström macroglobulinemia